Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New anticancer combination associated with high efficacy in phase II metastatic breast cancer trial

Jan. 13, 1998

Analog II: a novel antiestrogen with selective activity against breast cancer

Jan. 13, 1998

Temodal submitted for approval in E.U.

Jan. 13, 1998

Potent, selective protein tyrosine kinase inhibitors for immune and hyperproliferative disorders

Jan. 13, 1998

Chemogene therapy: a new therapeutic approach on the horizon?

Jan. 13, 1998

CDK inhibitor induces apoptosis and tumor necrosis in a dog with malignant melanoma

Jan. 12, 1998

FDA approves Photofrin for early-stage lung cancer

Jan. 12, 1998

New mycotoxin with antitumor and favorable hematological effects

Jan. 12, 1998

Good in vitro activity reported for Novartis PKC inhibitor

Jan. 12, 1998

Merck continues to devote extensive R&D efforts to FTase inhibitors

Jan. 12, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...